Tirzepatide Dosing
US$ 24.39
retatrutide phase 2 nejm weight loss 48 weeks percent 🚨 BREAKING: Shows “Bariatric-Level” in 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most 🧬 The Future of Weight
Description
Discontinuation rates in TRIUMPH-4 12.2% of participants on 9mg and 18.2% on 12mg discontinued treatment, notably higher than Phase 2 rates
10.1001/jamaophthalmol.2025.1455
That is an inference from the variability recognized in current labeling, not a fixed rule
Understanding whether this symptom stems directly from semaglutide's mechanism, indirect factors like reduced fluid intake, or concurrent medications helps patients and clinicians address concerns appropriately and maintain treatment adherence
Gregori N, ikonja J, Jane A, Jensterle M
